Stock Scorecard
Stock Summary for Syndax Pharmaceuticals Inc (SNDX) - $21.60 as of 12/26/2025 12:04:01 PM EST
Total Score
6 out of 30
Safety Score
33 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for SNDX
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for SNDX
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for SNDX
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for SNDX
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for SNDX (33 out of 100)
| Stock Price Rating (Max of 10) | 7 |
| Historical Stock Price Rating (Max of 10) | 7 |
| Stock Price Trend (Max of 10) | 0 |
| Book Value (Max of 10) | 2 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 8 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for SNDX
Financial Details for SNDX
Company Overview |
|
|---|---|
| Ticker | SNDX |
| Company Name | Syndax Pharmaceuticals Inc |
| Country | USA |
| Description | Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in Waltham, Massachusetts, dedicated to developing cutting-edge therapies for cancer treatment. With a promising pipeline that includes innovative agents utilizing immuno-oncology and epigenetic modulation, Syndax aims to address significant unmet medical needs across a range of malignancies. The company is committed to advancing its clinical programs, seeking to enhance patient outcomes and solidify its position as a pivotal player in the rapidly evolving cancer therapeutics market. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 9/30/2025 |
| Next Earnings Date | 3/9/2026 |
Stock Price History |
|
| Last Day Price | 21.60 |
| Price 4 Years Ago | 21.89 |
| Last Day Price Updated | 12/26/2025 12:04:01 PM EST |
| Last Day Volume | 887,064 |
| Average Daily Volume | 2,023,039 |
| 52-Week High | 22.73 |
| 52-Week Low | 8.58 |
| Last Price to 52 Week Low | 151.75% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 72.45 |
| Sector PE | 128.95 |
| 5-Year Average PE | 4.71 |
| Free Cash Flow Ratio | 16.12 |
| Industry Free Cash Flow Ratio | 14.50 |
| Sector Free Cash Flow Ratio | 31.21 |
| Current Ratio Most Recent Quarter | 4.64 |
| Total Cash Per Share | 1.34 |
| Book Value Per Share Most Recent Quarter | 1.33 |
| Price to Book Ratio | 16.04 |
| Industry Price to Book Ratio | 11.14 |
| Sector Price to Book Ratio | 43.34 |
| Price to Sales Ratio Twelve Trailing Months | 16.63 |
| Industry Price to Sales Ratio Twelve Trailing Months | 38.48 |
| Sector Price to Sales Ratio Twelve Trailing Months | 21.21 |
| Analyst Buy Ratings | 12 |
| Analyst Strong Buy Ratings | 2 |
Share Statistics |
|
| Total Shares Outstanding | 86,915,000 |
| Market Capitalization | 1,877,364,000 |
| Institutional Ownership | 120.08% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -52.25% |
| Reported EPS 12 Trailing Months | -3.60 |
| Reported EPS Past Year | -2.51 |
| Reported EPS Prior Year | -3.73 |
| Net Income Twelve Trailing Months | -311,577,000 |
| Net Income Past Year | -318,758,000 |
| Net Income Prior Year | -209,360,000 |
| Quarterly Revenue Growth YOY | 267.00% |
| 5-Year Revenue Growth | 73.25% |
| Operating Margin Twelve Trailing Months | -125.20% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 116,808,000 |
| Total Cash Past Year | 154,083,000 |
| Total Cash Prior Year | 295,394,000 |
| Net Cash Position Most Recent Quarter | -214,757,000 |
| Net Cash Position Past Year | -177,482,000 |
| Long Term Debt Past Year | 331,565,000 |
| Long Term Debt Prior Year | 59,894,664 |
| Total Debt Most Recent Quarter | 331,565,000 |
| Equity to Debt Ratio Past Year | 0.46 |
| Equity to Debt Ratio Most Recent Quarter | 0.26 |
| Total Stockholder Equity Past Year | 288,124,000 |
| Total Stockholder Equity Prior Year | 554,196,000 |
| Total Stockholder Equity Most Recent Quarter | 115,430,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -311,011,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -3.58 |
| Free Cash Flow Past Year | -274,903,000 |
| Free Cash Flow Prior Year | -160,601,000 |
Options |
|
| Put/Call Ratio | 0.65 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.00 |
| MACD Signal | 0.00 |
| 20-Day Bollinger Lower Band | 0.00 |
| 20-Day Bollinger Middle Band | 0.00 |
| 20-Day Bollinger Upper Band | 0.00 |
| Beta | 0.48 |
| RSI | 0.00 |
| 50-Day SMA | 0.00 |
| 150-Day SMA | 0.00 |
| 200-Day SMA | 0.00 |
System |
|
| Modified | 12/27/2025 8:11:47 AM EST |